银翘散合麻杏石甘汤治疗慢性阻塞性肺疾病急性加重期患者的临床效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (673 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate clinical efficacy of Yinqiao Powder combined with Maxing Shigan Decoction in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods One hundred and ninety-eight patients with acute exacerbation of COPD admitted to Jiaxing Hospital of Traditional Chinese Medicine (TCM) in Zhejiang Province from March 2015 to March 2018 were selected, they were divided into control group (n = 99) and study group (n = 99) according to the random number table method. Control group was treated with conventional Western medicine. Study group was treated with Yinqiao Powder and Maxing Shigan Decoction on the basis of control group. Clinical efficacy, TCM symptom score, pulmonary function, levels of inflammatory factors and incidence of adverse reactions were compared between two groups. Results After treatment, the scores of TCM syndromes in two groups were lower than those before treatment (P < 0.05), and those in study group were lower than those in control group (P < 0.05). Total clinical effective rate of study group was higher than that of control group (P < 0.05). After treatment, forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) of two groups were higher than before treatment, FEV1/FVC of two groups was higher than before treatment, and the improvement of study group was better than that of control group (P < 0.05). After treatment, the serum levels of interleukin-6, leukotrienes B4 and tumor necrosis factor-α in two groups were lower than those before treatment, and study group was lower than control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion Yinqiao Powder and Maxing Shigan Decoction combined with routine Western medicine in the treatment of acute exacerbation of COPD can rapidly improve the clinical symptoms of patients with significant curative effect, effectively improve the pulmonary function of patients, reduce the level of inflammatory factors, drug safety is better, clinical application value is higher.

Key words： Yinqiao Powder combined with Maxing Shigan Decoction Western medicine Chronic obstructive pulmonary disease Acute exacerbation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Haiming WANG Qunping ZHANG Feng

Cite this article:

WANG Haiming WANG Qunping ZHANG Feng. Clinical effect of Yinqiao Powder combined with Maxing Shigan Decoction in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease[J]. 中国医药导报, 2020, 17(16): 121-124.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I16/121

[1] Biener AI，Decker SL，Rohde F. Prevalence and treatment of chronic obstructive pulmonary disease （COPD） in the United States [J]. JAMA，2019，322（7）：602.
[2] Stamenova V，Yang R，Engel K，et al. Technology-enabled self-monitoring of chronic obstructive pulmonary disease with or without asynchronous remote monitoring：protocol for a randomized controlled trial [J]. JMIR Res Protoc，2019，8（8）：e13920.
[3] Vasiljevic S，Petrovic M，Cvetkovic A，et al. Relationship between incidence of chronic obstructive pulmonary disease and lung cancer as comorbidity in primary health care in two Belgrade communities [J]. J Buon，2019，24（3）：963-966.
[4] 贺辉.麻杏石甘汤合银翘散加减治疗小儿风热闭肺型肺炎喘嗽效果观察[J].内蒙古医学杂志，2019，51（4）：481-482.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南[J].中华内科杂志，2002，41（9）：640-646.
[6] 国家中医药管理局.中医内科病证诊断疗效标准（三）[J].湖北中医杂志，2002，24（4）：57.
[7] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002.
[8] 曹晓伟，唱浩，王延学，等.慢性阻塞性肺疾病患者病情转归与生存质量关系的研究[J].国际呼吸杂志，2018，38（9）：652-656.
[9] Dziankowska-Zaborszczyk E，Bryla M，Ciabiada-Bryla B，et al. Standard expected years of life lost （SEYLL） due to chronic obstructive pulmonary disease （COPD） in Poland from 1999 to 2014 [J]. PLoS One，2019，14（3）：e0213581.
[10] Hashemi-Bajgani SM，Abbasi F，Shafahi A，et al. Association of bile acid and pepsin micro-aspiration with chronic obstructive pulmonary disease exacerbation [J]. Tanaffos，2019，18（1）：52-57.
[11] 刘洋，汤万权.补肺活血汤联合常规西医治疗可降低气道炎症并改善肺功能从而提高COPD的疗效[J].中国免疫学杂志，2016，32（7）：992-995.
[12] 苏慧岚.中医外治法治疗慢性阻塞性肺疾病临床研究进展[J].实用中医药杂志，2019，35（7）：903-905.
[13] 许晓辰，钟春苗，傅恺，等.丹参川芎嗪对慢性阻塞性肺疾病急性加重期序贯机械通气患者呼吸功能的影响[J].中国现代医生，2019，57（14）：27-30.
[14] 骆国平，莫翠英，袁古治，等.三子养亲汤加减对慢性阻塞性肺疾病急性加重期患者IL-32表达的影响[J].中国现代医生，2019，57（9）：13-15，20.
[15] 梅玉霞，傅伟，吴睿峰.麻杏石甘汤合银翘散加减治疗小儿支气管肺炎30例临床观察[J].实用中西医结合临床，2014，14（6）：71-72.
[16] 吉建中.麻杏石甘汤治疗支气管哮喘急性发作期的临床疗效分析[J].内蒙古中医药，2017，36（14）：24.
[17] 刘阿玲，李红梅，李玲玲.麻杏石甘汤结合阿奇霉素治疗儿童支原体肺炎[J].国际中医中药杂志，2018，40（12）：1125-1128.
[18] 郑立，陈彩明，唐悦婵.舒利迭联合标准桃金娘油肠溶胶囊治疗慢性阻塞性肺疾病的疗效及对血清SIRT1 sfrp5 MRpro-ADM的影响[J].河北医学，2019，25（6）：961-965.
[19] 折哲，石克华.复方佛耳草合剂对慢性阻塞性肺疾病急性加重患者气道炎症的影响[J].西部中医药，2018，31（9）：5-8.
[20] 吴建顺，池燕，曹得胜，等.温阳活血汤对稳定期慢性阻塞性肺疾病脾肾阳虚证患者炎性反应因子的影响[J].世界中医药，2018，13（10）：2453-2455，2459.
[21] 虞玉英，胡克崇，徐慧芳，等.布地奈德联合孟鲁司特钠对慢性阻塞性肺疾病患者肺功能及血清中IL-6、IL-8和TNF-α的影响[J].中国生化药物杂志，2014，34（7）：153-155.
[22] 洪春霖，洪敏俐，陈慧暖，等.愈肺宁方对慢性阻塞性肺疾病稳定期患者诱导痰炎症细胞和LTB4的影响[J].世界科学技术-中医药现代化，2015，17（12）：2517-2521.
[23] 郭晓燕，腾飞，张惠勇，等.川芎平喘合剂治疗慢性阻塞性肺疾病的随机对照研究[J].西部中医药，2018，31（1）：1-4.
[24] 古远云，钟洪卫，陈辉，等.参蛤益肺胶囊对COPD稳定期老年患者LTB4、IL-8、TNF-α影响的研究[J].世界中医药，2016，11（9）：1697-1699.
[25] 梁炜，杨红梅，梁爱武，等.银杏叶提取物对慢性阻塞性肺疾病大鼠CRP、TNF-α的影响[J].实用医学杂志，2017， 33（12）：1936-1938.
[26] 仇年芳，童蓓丽，章琴，等.疏风润肺方联合布地奈德对慢性阻塞性肺疾病急性加重期伴肺炎患者气道重塑状态的改善作用[J].世界中医药，2019，14（11）：3005-3008，3012.
[27] 别心坦.麻杏石甘汤联合抗生素治疗伴心肌损害肺炎支原体肺炎疗效观察[J].现代中西医结合杂志，2016，25（17）：1876-1879.